Skip to main content

Unnecessary Pap Tests in Millions of US Women


In their report on cervical cancer screening released yesterday, the Centers for Disease Control and Prevention (CDC) startlingly estimated that 22 million women in the United States may have undergone such screening unnecessarily, because they had already had hysterectomies.
An expert approached by Medscape Medical News to comment on the issue cautioned that the data collected by the CDC were from women self-reporting and so may be subject to bias. She also suggested that some of the unnecessary testing, which is contrary to guidelines that have been in place for a decade, may be due to confusion stirred up by educational campaigns for the human papilloma virus vaccine Gardasil (Merck & Co).
The CDC analyzed data collected from 2000-2010 by the Behavioral Risk Factor Surveillance System on screening for cervical cancer using the Papanicolaou (Pap) test.
In one of the articles published in Morbidity and Mortality Weekly Report, the CDC highlighted the fact that during the study period, screening in women after a hysterectomy had declined from 73.3% in 2000 to 58.7% in 2010. But this means that more than one half of the women were undergoing Pap tests unnecessarily, because hysterectomy involves removal of the cervix in the majority of cases (94% of cases, the CDC estimates).
Such women do not need cervical cancer screening — and it has been specifically discouraged in guidelines from all the major organizations since 2002-2003.
Several media reports highlighted this finding and emphasized the huge waste of financial resources this involves.
The CDC itself commented that in this population, any benefit from screening "might be outweighed by the net harm." Such harm may include false-positive tests leading to needless patient anxiety and invasive procedures.
"The false-positive rate...is indeed a great potential harm to women and cost to the healthcare system," says Diane Harper, MD, MPH, professor of community and family medicine/obstetrics and gynecology at Dartmouth Medical School, in Hanover, New Hampshire, and director of the Gynecologic Cancer Prevention Research Group at the Norris Cotton Cancer Center.
Medscape Medical News approached Dr. Harper to shed some light on some of the findings from the survey.
Self-Report Data Are Subject to Bias
Dr. Harper emphasized that the data are based on self-reporting, and thus are subject to bias.
"We have ample evidence to show that women of all ages are not cognizant of what a Pap test is," Dr. Harper said. "Most women believe that anytime they have an examination of the pelvic area, whether a speculum was used or not, they had a Pap test."
This has been shown in multiple research studies, and it raises questions concerning the validity of the self-report nature of the CDC survey, she said. "Hence, what is really being compared is whether women's perceptions of having had a Pap test have changed with the new guidelines."
"The second issue with the CDC survey data," she continued, "is that the answers women can choose for frequency of Pap testing are hard for women to internalize. Most women can distinguish 'never' from'ever' And most women can distinguish within the past 12 months/year. But at frequencies longer than a year, there is very poor recall accuracy, leading to tremendous bias how the data are interpreted."
Merck Education Created Confusion
Commenting specifically about the data on Pap tests done after hysterectomy, Dr. Harper puts some blame onto the Merck advertising/educational campaigns for Gardasil, which emphasize how human papilloma virus (HPV) is related to vaginal, vulvar, anal, and cervical cancers. These campaigns have "left most of the population and many ob/gyn as well as primary care doctors very confused about how to detect these increasingly more common HPV-related cancers," she told Medscape Medical News.
"It does not surprise me that physicians have taken a woman's risk for HPV exposure (number of sexual partners or past HPV infection) and stated that even with a hysterectomy for reasons other than HPV, there is no other way than a Pap test to determine if a vaginal cancer is beginning. There are a number of incorrect assumptions in that line of thinking, but that line of thinking has been spawned after the intense advertising campaign Merck undertook for their HPV vaccine," she said.
In its report, the CDC also mentions vaginal cancer as a reason cited by proponents of continued screening after hysterectomy. "However, vaginal cancer is rare, and the value of cytology tests to detect vaginal cancer in the absence of a cervix is unknown," the agency points out.
Unnecessary Testing in Other Groups
The CDC survey also highlighted several other groups of women who are undergoing cervical cancer screening unnecessarily and contrary to guidelines.
Although there had been some variation in recommendations made by different organizations in the past, updated guidelines released last year saw a convergence of opinions and very similar recommendations issued by the American Cancer Society, the American College of Obstetricians and Gynecologists, and the US Preventive Services Task Force.
In the new guidelines, there were specific recommendations that cervical cancer screening should begin at age 21 years, and not before, and yet data from the CDC survey suggest that Pap testing is being carried out in 18- to 21-year-olds.
That may not be the case. Dr. Harper explained that what these young 18- to 21-year-old women were reporting as a Pap test may actually have been a test for chlamydia, "which is prime in this age group."
Although it can be tested via urine, a chlamydia test is often done via a cervical sampling (ie, by a pelvic examination with a speculum), she explained. "Hence, a woman 18 to 21 who was being screened for chlamydia may have reported that she also had a Pap test done, not really knowing whether she did or not. Most of the time, the nurse practitioners or physicians who do the sample collection only report back that the results are 'normal' and not specifically that a chlamydia test was negative and a cytology test showed no abnormal cells."
"The other 'quiet' reason is that the incidence of cervical cancer in the US in women under the age of 21 is 1.7/100,000. This is a real number, and this means that real young women get cervical cancer, and some of them die," Dr. Harper added.
"However, cytology is only good enough to reduce cervical cancer to 2.8/100,000, so getting Pap testing does not allow us to detect this small but real number of young women with cervical cancer. Adding HPV testing to cytology in this age group just creates a very large number of false positives. Hence, the reality is that we have no perfect system — Gardasil can only reduce the cervical cancer rate to 14/100,000, which is worse than Pap screening and not a way to protect all of the 1.7/100,000 young adolescents from cervical cancer. Hence, we accept that some cervical cancers will not be detected," she said.
Practice Changes Take Time
Another finding from the CDC survey was data suggesting that women in the 22- to 30-year-old age group were undergoing Pap tests annually instead of every 3 years, as per the new, updated guidelines.
This as well as some of the other findings suggest that it is taking some time for recommendations in the guidelines to filter through to clinical practice. Dr. Harper offers a few suggestions as to why this is the case: physicians may not be understanding the evidence for the change in the screening recommendations; reimbursement for the test still occurs; the patient feels at risk and requests frequent testing ("or the same testing as my sisters had..."); and nursing staff may set up the clinic rooms not understanding or accepting the change in guidelines.
"All past analyses have shown that it takes about 10 years for physician behaviors to change to reflect the latest change in screening recommendations," Dr. Harper noted.
Also approached for comment was Maurie Markman, MD, vice president of patient oncology services and national director for medical oncology at the Cancer Treatment Centers of America, and clinical professor at Drexel University College of Medicine, Philadelphia, Pennsylvania. Dr. Markman writes theMarkman on Oncology blog for Medscape Medical News.
"There are a number of possible explanations for why physicians continue to obtain Pap smears in settings where the evidence suggests limited utility," he explained. First, "individual physicians have been obtaining these tests routinely in these groups in the past, and it may not be easy to change existing practice patterns," Dr. Markman noted. In addition, "other 'screening' tests are obtained yearly (mammogram) and it may be easier to organize all such testing at the same time," he said. Also playing a role are patient requests/expectations and practice economics, he added.
"I believe the major point to be made is that this experience demonstrates the complexity of changing established and known effective practice, even with the firm and rational recommendation of national clinical organizations" Dr. Markman said.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...